Modern insights of nanotheranostics in the glioblastoma: An updated review
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2025
DOI: 10.1016/j.bbadis.2024.167653 ↗At a glance
Übersichtsarbeit in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2025. Written by Roopkumar Sangubotla and 3 co-authors. Institution: Department of Chemical and Biological Engineering, Gachon University, 1342 Seongnam Daero, Seongnam-Si, Gyeonggi-Do 13120, Republic of Korea. Major MEDLINE topics: Glioblastoma, Theranostic Nanomedicine, Brain Neoplasms, Nanoparticles. Cited 4 times so far (Crossref); 195 references. Funded by: Gachon University, National Research Foundation of Korea, Ministry of Education.
Abstract (original language)
Glioblastoma multiforme (GBM) is a highly malignant subtype of glioma, originating from the glial cells that provide support to other neurons in the brain. GBM predominantly impacts the cerebral hemisphere of the brain, with minimal effects on the cerebellum, brain stem, or spinal cord. Individuals diagnosed with GBM commonly encounter a range of symptoms, starting from auditory abnormalities to seizures. Recently, cell membrane-camouflaged nanoparticles (CMCNPs) are evolving as promising theranostic agents that can carry specific biological moieties from their biological origin and effectively target GBM cells. Moreover, exosomes have gained widespread scientific attention as an effective drug delivery approach due to their excellent stability in the bloodstream, high biocompatibility, low immune response, and inherent targeting capabilities. Exosomes derived from specific cell types can transport endogenous signaling molecules that have therapeutic promise for GBM therapy. In this context, researchers are utilizing various techniques to isolate exosomes from liquid biomarkers from patients, such as serum and cerebrospinal fluid (CSF). Proper isolation of exosomes may induce the clinical diagnosis in GBM due to their commercial accessibility and real-time monitoring options. Since exosomes are unable to penetrate the blood-brain barrier (BBB), strategic theranostic methods are ideal. For this, understanding interactions between glioma-specific exosomes in the TME and biomarkers is necessary. The versatile characteristics of NPs and their capacity to cross the BBB enable them to be indispensable against GBM. In this review article, we discussed the recent theranostic applications of nanotechnology by comparing the limitations of existing nanotechnology-based approaches.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Chemical and Biological Engineering, Gachon University, 1342 Seongnam Daero, Seongnam-Si, Gyeonggi-Do 13120, Republic of Korea.
- GITAM School of Pharmacy, GITAM Deemed to be University, Rudraram, Patencheru, Sangareddy Dist, 502329, Telangana, India.
- Department of Zoology, Sri Venkateswara University, Tirupati, Andhra Pradesh 517502, India.
- Department of Chemical and Biological Engineering, Gachon University, 1342 Seongnam Daero, Seongnam-Si, Gyeonggi-Do 13120, Republic of Korea. Electronic address: jongkim@gachon.ac.kr.
Funding
- Gachon University
- National Research Foundation of Korea
- Ministry of Education
Cite
APA
Sangubotla, R., Gubbiyappa, K. S., Devarapogu, R., & Kim, J. (2025). Modern insights of nanotheranostics in the glioblastoma: An updated review. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. https://doi.org/10.1016/j.bbadis.2024.167653
Vancouver
Sangubotla R, Gubbiyappa KS, Devarapogu R, Kim J. Modern insights of nanotheranostics in the glioblastoma: An updated review. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2025. doi:10.1016/j.bbadis.2024.167653
BibTeX
@article{Sangubotla2025,
author = {Sangubotla, Roopkumar and Gubbiyappa, Kumar Shiva and Devarapogu, Rajakumari and Kim, Jongsung},
title = {Modern insights of nanotheranostics in the glioblastoma: An updated review},
journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
year = {2025},
doi = {10.1016/j.bbadis.2024.167653}
}
EUVIMED